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Abstract 
Surface tension at the surface-to-air interface is a physico-chemical property of liquid pharmaceutical formulations 
that are often overlooked. To determine if a trend between surface tension and route of administration exists, a suite 
of oral, nasal, and ophthalmic drug formulations were analyzed. The surface tension at the surface-to-air interface of 
the oral formulations studied were in or above the range of the surface tension of gastric, duodenum, and jejunum 
fluids. The range of surface tensions for oral formulations were 36.6–64.7 dynes/cm. Nasal formulations had surface 
tensions below that of the normal mucosal lining fluid with a range of 30.3–44.9 dynes/cm. Ophthalmic OTC formu-
lations had the largest range of surface tensions at the surface-to-air interface of 34.3–70.9 dynes/cm; however, all 
formulations indicated for treatment of dry eye had surface tensions higher than that of normal tears, while those for 
treatment of red eye had surface tensions below. Therefore, surface tension at the surface-to-air interface of liquid 
formulations is dependent on the route of administration, environment at site of introduction, and for ophthalmics, 
what the formulation is indicated for.
© 2016 The Author(s) This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Liquid drug delivery systems undergo extensive experi-
mental testing beyond pharmacodynamic and pharma-
cokinetic studies, such as pH, viscosity, density, stability, 
leachable studies, isotonicity, etc. A parameter that is 
often overlooked is surface tension at the surface-to-air 
interface. This is more understandable for oral or paren-
teral liquid dosage forms since they are quickly distrib-
uted in the physiological aqueous media of the body. 
However, for ophthalmic and nasal formulations, which 
have much greater interaction with the air, this knowl-
edge may have a greater impact on efficiency of the deliv-
ery of the drug. Surface tension is derived from a liquid’s 
elastic tendency. The layer of molecules on the surface 
attempt to minimize their overall surface area by being 
attracted to molecules in the bulk liquid. It is well known 
that surface tension is considered a critical parameter in 
other areas with significant liquid–air exposures, such as 
spray dryer, [1] fuel injection, [2] childhood interstitial 
lung diseases (chILD), [3] as well as by us recently in the 
determination of the pKa values of polymers [4] . The sur-
face tension of ophthalmic and nasal formulations affects 
the rate of its evaporation, the interaction with the lac-
rimal film of tears or the airway mucosal lining, as well 
as how easily it would spread along a biological surface. 
To minimize irritation one would expect that liquid for-
mulations in general would mimic the natural surface 
tension of the particular area of administration and thus 
maximize interactions. At the onset of this study we had 
anticipated that the surface tension at the surface-to-air 
interface for ophthalmic and nasal formulations would be 
in a very narrow range centered near that of body’s physi-
ological environment and that oral formulations would 
have a much broader range of surface tensions. Herein, 
we report our findings on the surface tensions at the sur-
face-to-air interface for a range of oral, nasal, and oph-
thalmic over-the-counter (OTC) drug substances.
Experimental part
Materials
Kaopectate® Max (Chattem Inc), CareOne™ Regular 
Strength Stomach Relief (Foodhold USA, Inc), CareOne™ 
Loperamide HCl Oral Suspension (Foodhold USA, Inc), 
Children’s Delsym® Cough  +  Cold Nitetime (Reckitt 
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Benckiser), Chloraseptic® Sore Throat (Medtech Products 
Inc), CareOne™ Multi-Symptom Nitetime Cold/Flu Relief 
(Foodhold USA, Inc), CareOne™ Non-Drowsy Daytime 
Cold/Flu Relief (Foodhold USA, Inc), CareOne™ Infants’ 
Ibuprofen Oral Suspension (Foodhold USA, Inc), Halo™ 
Oral Antiseptic (Oasis Consumer Healthcare, LLC), Con-
centrated Motrin®’s Infants’ Drops (McNeil Consumer 
Healthcare), Afrin® No Drip Extra Moisturizing (MSD 
Consumer Care, Inc), Afrin® Original Nasal Spray (MSD 
Consumer Care, Inc), CareOne® No Drip Nasal Spray 
(American Sales Co), Zicam® Intense Sinus Relief No 
Drip Liquid Nasal Gel (Matrixx Initiatives, Inc), Mucinex® 
Sinus-Max (Reckitt Benckiser), 4 Way® Nasal Decongest-
ant Fast Acting Spray (Novartis Consumer Health, Inc), 
Vicks® Sinex 12 Hour Decongestant Nasal Spray (Procter 
& Gamble), NeoSynephrine® Cold & Sinus Mild Strength 
Spray (Bayer HealthCare LLC), CareOne® Saline Nasal 
Spray—Nasal Moisturizing Spray (American Sales Co), 
Vicks® Non-Drowsy Qlear Quil 12 Hour Nasal Decongest-
ant Moisturizing (Procter & Gamble), TheraTears® Lubri-
cant Eye Drops (Advanced Vision Research, Inc), Refresh® 
Liquigel Lubricant Eye Gel (Allergan, Inc), Refresh® Optive 
Lubricant Eye Drops (Allergan, Inc), Systane® Ultra High 
Performance (Alcon Laboratories, Inc), Systane® Gel 
Drops Anytime Protection (Alcon Laboratories, Inc), Clear 
Eyes® Contact Lens Multi-Action Relief, Systane® Balance 
Restorative Formula (Alcon Laboratories, Inc), Visine-A® 
Multi-Action Allergy Relief (Johnson & Johnson Health-
care Products), Clear Eyes® Redness Relief (Medtech Prod-
ucts Inc), and CareOne™ Sterile Eye Drops (American Sales 
Co) were all freshly purchased from a local pharmacy, were 
non-expired, and used as is. Where multiple containers 
were need it was ensured that identical lots were employed.
Surface tension determination
Surface tension at the surface-to-air interface was meas-
ured at room temperature in sextuplicate using a surface 
tensiometer (CSC-DuNOÜY, Central Scientific Co, Inc) 
with a 6  cm platinum tensiometer ring (Thomas Scien-
tific). Using the correction Eq. (1), actual surface tension 
values were obtained.
where F  =  the correction factor; R  =  the radius of 
the ring; r =  the radius of the wire of the ring; P =  the 
apparent value or dial reading; D  =  the density of 
the lower phase; d  =  the density of the upper phase; 
K =  0.04534 – 1.679 r/R; C =  the circumference of the 
ring; a = 0.7250; b = 0.0009075.
Results and discussion
At the onset, we would like to make clear that the objec-
tive of this non-externally funded study is not to report 
(1)(F − a)2 = 4b/(piR)2 × P/(D − d) + K
on which drug formulation is “better” nor on which sur-
face tension at the surface-to-air interface is “optimal” 
for any class of drug. To ensure this, no surface tension 
measurements were compared to their respective manu-
facturers’ reported values, if available. Furthermore, no 
grandiose conclusions were made regarding the efficacy 
of the formulations studied. We choice a du Noüy ring 
tensiometer for measuring the surface tension at the 
surface-to-air interface for this study. Briefly, a platinum 
ring is lowered into a solution that is being analyzed until 
completely submerged. Upon pulling the ring up and 
out of the solution, the force needed to ultimate break 
contact of the ring to the solution is measured. We ini-
tially began by exploring various oral formulations. We 
selected 10 OTC products with a range of pharmaco-
logical activity. Indications for the formulations studied 
include: pain/fever relief, anti-diarrheal, decongestant, 
antiseptic, antihistamine, indigestion, etc. CareOne™ 
brands were our most commonly utilized product line, 
not by design but rather by necessity as they had the 
widest range of OTC products available at the local 
pharmacy. We hypothesized that the surface tension at 
the surface-to-air interface of oral formulations would 
have a large range, since, upon clinical administration 
of the medication, the liquids would be quickly distrib-
uted throughout the significantly large volume of the GI 
tract. The surface tension at the surface-to-air interface at 
room temperature of the gastric fluids in the fasting state 
have been reported to be in the range of 31–45 dynes/cm 
(medium of 36.8 dynes/cm), [5] which is very similar to 
that of the duodenal fluids of ~37 dynes/cm [6, 7]. Jejunal 
fluids have been reported to have a slightly lower surface 
tension of  ~30.5 dynes/cm [5]. This lowering of surface 
tension has been hypothesized to be due to decreased 
secretion of bile salts from the gall bladder compared to 
the duodenum (~2.5 mM compared to ~3.3 mM, respec-
tively) [5]. There is a reported lowering of surface tension 
for all intestinal fluids in the fed state to 30.5 [5, 7], 31.3 
[3, 5] and 30.0  dynes/cm, [8] for gastric, duodenal, and 
jejunal fluids respectively. In contrast, deionized water 
has a surface tension of 72.2  dynes/cm [9]. Since the 
reported surface tension of the fluids in the GI tract were 
determined at room temperature, the oral OTC formula-
tions were also done at that temperature. It is known that 
as temperature increases, surface tension decreases. For 
example with deionized water there is a drop in surface 
tension from 71.99 to 70.41 dynes/cm as the tempera-
ture is increased from 25 to 35 °C [10]. All ten of the oral 
OTC formulations examined had surface tensions at the 
surface-to-air interface greater than the surface tension 
of the GI fluids at the fed state, and with one exception, 
above the fasting state (Table 1). Motrin®’s Infant Drops 
had the lowest surface tension of the formulations we 
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tested, at 36.6 dynes/cm. The formulation with the high-
est surface tension, at 64.7  dynes/cm, was the antidiar-
rheal, Kaopectate® Max. Non-electrolytes dissolved in an 
aqueous solution tend to lower the surface tension at the 
surface-to-air interface. Thus, it was not surprising that 
all formulations examined were below 72.2 dynes/cm. 
Compared to the other oral formulation, Kaopectate® 
Max, CareOne™ Loperamide Hydrochloride, and Care-
One™ Regular Strength Stomach Relief had the greatest 
surface tension values, and of those tested were the only 
three that contained derivatized cellulose. The most com-
monly employed excipient in the oral formulations were 
glycerin (7 liquids), propylene glycol (4 liquids), and poly-
ethylene glycol (3 liquids). These have surface tensions 
of 63.4, 40.1, and 44.0 dynes/cm, [11] respectively, which 
partially explains the lowered surface tensions. Nonethe-
less, the range of surface tensions at the surface-to-air 
interface for the oral formulations examined was between 
36.6 and 64.7 dynes/cm, or a difference of 28.1 dynes/cm.
For nasal formulations, we again selected 10 OTCs 
from a range of manufacturers. Not surprising, most 
were nasal decongestant, whether for allergies or treating 
symptoms of the common cold. The normal surface ten-
sion of the upper airway mucosal lining liquid has been 
reported to be  ~56 dynes/cm [12]. The temperature of 
the upper airway has been reported to be slightly higher 
than room temperature at ~30  °C [13]. This would only 
produce a difference of <1 dyne/cm hence our study was 
conducted at room temperature. All the nasal formula-
tions had a surface tension at the surface-to-air inter-
face lower than the surface tension of the upper airway 
mucosal lining liquid (Table 2). The lower the surface ten-
sion of a solution, the less intermolecular forces present, 
which in turn enables it to wet a surface more readily. 
Similar to the oral formulations discussed above, some 
nasal solutions contained glycerin, derivatized cellu-
lose, propylene glycol, and/or polyethylene glycol, all of 
which would lower the surface tension relative to deion-
ized water. One ingredient that was found in all 10 nasal 
OTCs was benzalkonium chloride (BAC). This is typically 
added as a preservative, however it also a surface active 
agent (i.e., a cationic surfactant) [11]. The surfactant may 
be serving multiple roles in the formulation. Beyond a 
preservative, it could be increasing the solubility of the 
active agent, as well as allowing for the formation of 
micelles [11]. The latter requires that the amount of BAC 
added be above the critical micelle concentration (CMC). 
Although the quantities used in the nasal formulations 
are not specified, the allowable range of BAC in nasal for-
mulations, by USP 34-NF 29 standards, is 0.002–0.02 % 
w/v, which could allow for micelle formation since the 
CMC of BAC is 0.0035 % w/v [14]. Regardless of micelle 
formation or not, the addition of the cationic surfactant 
lowers the surface tension at the surface-to-air inter-
face. The lower surface tension of the nasal formulations 
allows for easier spreading over the surface, and therefore 
increase drug distribution and absorption.
We had initially hypothesized that the surface tension at 
the surface-to-air interface for ophthalmic solutions would 
have the narrowest range and be very similar to that of 
normal tears (~43 dynes/cm) [15]. The temperature of the 
cornea has been reported to be only slightly higher than 
room temperature at <29 °C [16]. We were surprised that 
not only were the surface tension values of many of the 
ten ophthalmic OTCs substantially different than normal 
tears (Table 3), the range of the surface tensions was also 
Table 1 Surface tension at the surface-to-air interface for oral OTC formulations
Solution Indication Surface tension  
(dynes/cm)
Kaopectate® Max Anti-diarrheal, relives nausea and upset stomach associated with diarrhea 64.7 ± 0.1
CareOne™ Regular Strength Stomach Relief Antihistamine for allergic reactions, motion sickness, cold, itching, nausea/
vomiting, sleep aid
59.6 ± 0.6
CareOne™ Loperamide HCl Oral Suspension Anti-diarrheal, traveler’s diarrhea 57.8 ± 0.7
Children’s Delsym® Cough + Cold Nitetime Cough, nasal congestion, symptoms of hay fever (sneezing, runny nose  
and itchy watery eyes)
49.0 ± 0.6
Chloraseptic® Sore Throat (Phenol/Oral Anesthetic) Upset stomach (indigestion/heartburn), anti-diarrhea, nausea, belching 44.6 ± 0.2
CareOne™ Multi-Symptom Nitetime Cold/Flu Relief Pain/fever reducer, cough suppressant, antihistamine 41.5 ± 0.1
CareOne™ Non-Drowsy Daytime Cold/Flu Relief Pain/fever reducer, cough suppressant, antihistamine 41.3 ± 0.2
CareOne™ Infants’ Ibuprofen Oral Suspension Pain and fever reducer 39.0 ± 0.7
Halo™ Oral Antiseptic Oral antiseptic 37.6 ± 0.4
Concentrated Motrin®’s Infants’ Drops Relieves fever and minor aches/pain due to common cold 36.6 ± 0.6
Gastric fluid ~36.8 fasting ~30.5 fed
Duodenum fluid ~37 fasting ~31.3 fed
Jejunum fluid ~30.5 fasting ~30.0 fed
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greater than for both the nasal or oral formulations. This 
was initially perplexing, however, when grouped into liq-
uids for the treatment of the symptoms of either dry eye 
or red eye, a pattern emerged. All the formulations that are 
indicated for red eye: Clear eyes® Redness relief, Visine-
A® Multi-Action Eye Allergy Relief, and CareOne™ Sterile 
Eye Drops, contain a vasoconstrictor, α-adrenergic agent, 
naphazoline hydrochloride or tetrahydrozoline hydro-
chloride, which would lower the aqueous surface tension. 
None of the other ophthalmic drops contain a small mol-
ecule drug. As is the case for nasal sprays, a surface tension 
lower than that of the environment in which the solution is 
being introduced is beneficial to ensure greater spreading 
and thus absorption of the drug. In addition, the lowering 
of the surface tension of the ophthalmic solutions was par-
tially due to the use of a surfactant, more accurately, BAC. 
Recently it has been reported that the introduction of BAC 
into human tears hinders the ability of native lipids to 
spread across the tear films and can result in the replace-
ment of those lipid with BAC molecules [17]. It has been 
suggested that this phenomenon has a negative impact on 
the tear film stability [17].
Table 2 Surface tension at the surface-to-air interface for nasal OTC formulations
Solution Indication Surface tension 
(dynes/cm)
Mucosal lining fluid ~56
Afrin® No Drip Extra Moisturizing Relieves nasal congestion due to common cold, hay fever, upper 
respiratory allergies; swollen nasal membranes, sinus congestion/
pressure
44.7 ± 0.8
Afrin® Original Nasal Spray Relieves nasal congestion due to common cold, hay fever, upper 
respiratory allergies; swollen nasal membranes, sinus congestion/
pressure
41.6 ± 0.3
CareOne® No Drip Nasal Spray Relieves nasal congestion; sinus congestion 40.6 ± 0.4
Zicam® Intense Sinus Relief No Drip Liquid Nasal Gel Relieves nasal congestion due to common cold, hay fever, allergies, 
and sinusitis; sinus congestion/pressure
37.4 ± 0.6
Mucinex® Sinus-Max Relieves nasal congestion, due to common cold, hay fever, upper 
respiratory allergies; sinus congestion/pressure
37.2 ± 0.4
4 Way® Nasal Decongestant Fast Acting Spray Relieves nasal congestion, sinus congestion/pressure, swollen nasal 
membranes
36.7 ± 0.4
Vicks® Sinex 12 Hour Decongestant Nasal Spray Relieves nasal congestion due to cold, hay fever, upper respiratory 
allergies
33.9 ± 0.2
NeoSynephrine® Cold & Sinus Mild Strength Spray Relieves nasal congestion due to cold, allergies 33.8 ± 0.2
CareOne® Saline Nasal Spray—Nasal Moisturizing Spray Relieves dry nasal membranes 33.1 ± 0.2
Vicks® Non-Drowsy Qlear Quil 12 Hour Nasal Decong. 
Moisturizing
Relieves nasal congestion due to cold, hay fever, other respiratory 
allergies; sinus congestion/pressure
30.3 ± 0.2
Table 3 Surface tension at the surface-to-air interface for ophthalmic OTC formulations
Solution Indication Surface ten-
sion (dynes/cm)
TheraTears® Lubricant Eye Drops Used to moisten dry eyes and also to relieve burning sensation, irritation and discom-
fort caused by dry eyes
70.9 ± 0.2
Refresh® Liquigel Lubricant Eye Gel Used for moderate to severe dry eye symptoms 66.4 ± 0.2
Refresh® Optive Lubricant Eye Drops Used to relieve dry, irritated eyes. Decreases symptoms such as irritation, burning 65.6 ± 0.2
Systane® Ultra High Performance Used to relieve dry, irritated eyes. Decreases symptoms such as irritation, burning 61.0 ± 0.3
Systane® Gel Drops Anytime Protection Used to relieve dry, irritated eyes. Decreases symptoms such as irritation, burning 54.3 ± 0.6
Clear Eyes® Contact Lens Multi-Action Relief Relieves dry eyes, rewets lenses, soothes and moisturizes, removes particles from 
lenses
54.1 ± 0.2
Systane® Balance Restorative Formula For the temporary relief of burning and irritation due to dryness of the eye 46.5 ± 0.4
Tears ~44
Visine-A® Multi-Action Allergy Relief Temporarily relieves itchy, red eyes due to: pollen, ragweed, grass, animal hair and 
dander
39.5 ± 0.2
Clear Eyes® Redness Relief Relieves redness of the eye due to minor eye irritations 37.1 ± 0.2
CareOne™ Sterile Eye Drops Relief of redness and irritation of the eye 34.3 ± 0.2
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All ophthalmic OTCs tested that are indicated for dry 
eye have surface tensions at the surface-to-air interface 
above the value for tears. The three ophthalmic solutions 
with the greatest surface tension at the surface-to-air 
interface are: Thera® Tears Lubricant Eye Drops, Refresh 
Liquigel®, and Refresh Optive® Lubricant Eye Drops, 
with values of 70.9, 66.4, and 65.6 dynes/cm, respectively. 
These three were the only solutions tested that contained 
the active ingredients, sodium carboxymethylcellulose, 
which is used to lubricate the eye. In addition to this 
macromolecule salt, all three solutions contained numer-
ous other electrolytes that contribute to higher surface 
tension values. Of the three products Refresh Optive® 
Lubricant Eye Drops has the lowest surface tension. It is 
the only one of the three that contains glycerin, which is 
known to lower the surface tension values. The remain-
ing four ophthalmic OTCs are all indicated for dry eye, 
and have surface tension values at the surface-to-air 
interface above the surface tension of tears and were in 
the range of 46.5–61  dynes/cm. The lubricants present 
in these four solutions are polyethylene glycol, propylene 
glycol, and/or glycerin.
Conclusions
All OTC formulations tested had surface tensions at the 
surface-to-air interface less than that of deionized water. 
For oral formulations, there was a broad range of surface 
tensions, however each was at or above the surface ten-
sions of gastric, duodenum, and jejunum fluids. For nasal 
formulations, all solutions had surface tension beneath 
the mucosal lining fluids. This allows for greater spread-
ing of the formulation on the surface. For ophthalmic for-
mulations, solutions indicated for treatment of red eye 
had surface tensions less than that of tears, presumably 
to allow for greater spreading. Ophthalmic solutions that 
were indicated for treatment of dry eye had surface ten-
sions greater than that of tears, most likely to increase the 
stability of the tear film and thus allow for greater lubri-
cation of the eye.
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